(Q34691359)

4 August 2017

1 reference

title

Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability (English)

1 reference

4 August 2017

1 reference

1 reference

Julio Pascual

1

1 reference

4 August 2017

Valentin Mateos

2

1 reference

4 August 2017

Carles Roig

3

1 reference

4 August 2017

Margarita Sanchez-Del-Rio

4

1 reference

4 August 2017

Dolores Jiménez

5

1 reference

4 August 2017

publication date

1 September 2007

1 reference

4 August 2017

1 reference

4 August 2017

volume

47

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

1152-1168

1 reference

Epidemiology of headache in Europe

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Ergotamine in the acute treatment of migraine: a review and European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Pharmacological treatments for acute migraine: quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Frovatriptan use in migraineurs with or at high risk of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Frovatriptan for the acute treatment of migraine: a dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Oral sumatriptan compared with placebo in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Dose range-finding studies with frovatriptan in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Eletriptan for the acute treatment of migraine: results of bridging a Japanese study to Western clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Sumatriptan and naproxen sodium for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2007.00849.X

10.1111/J.1526-4610.2007.00849.X

21 January 2018

Identifiers

DOI

1 reference

release_oytm3yahubhqvniw6doszwitwe

4 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oytm3yahubhqvniw6doszwitwe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference